Vinpocetine ameliorates acute hepatic damage caused by administration of carbon tetrachloride in rats

Acta Biologica Hungarica

Volumn 58, Issue 4, 2007, Pages 411-419

  Abdel Salam, O M E ^a   Hassan Oraby, Fatma ^a   Hassan, Nabila S ^a  

^a NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Carbon tetrachloride; Liver injury; Rat; Silymarin; Vinpocetine

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CARBON TETRACHLORIDE; VINCA ALKALOID; VINPOCETINE;

ANALYSIS OF VARIANCE; ANIMAL; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DOSE RESPONSE; LIVER DISEASE; MORPHOMETRICS; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ANALYSIS OF VARIANCE; ANIMALS; ASPARTATE AMINOTRANSFERASES; BODY WEIGHTS AND MEASURES; CARBON TETRACHLORIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; LIVER DISEASES; RATS; RATS, SPRAGUE-DAWLEY; VINCA ALKALOIDS;

RATTUS;

EID: 38549143648     PISSN: 02365383     EISSN: 1588256X     Source Type: Journal    
DOI: 10.1556/ABiol.58.2007.4.8     Document Type: Article

References (31)

1. Arif, A., Levine, R. A., Sanderson, S. O., Bank, L., Velu, R. P., Shah, A., Mahl, T. C., Gregory, D. H. (2003) Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig. Dis. Sci. 48, 1425-1430.
2. Bacon, B. R. (2004) Managing hepatitis C. Am. J. Manag. Care 10, S30-S40.
3. Bauer, J. D. (1982) Clinical Laboratory Methods. The C. V. Mosby Co., St. Louis, Toronto, London.
4. Bedossa, R. (1999) Natural history of liver fibrosis. Adv. Liver. Pathol. 32, 292-293.
5. Belfield, A., Goldberg, D. M. (1971) Revised assay for serum phenyl phosphatase activity using 4-amino-antipyrine. Enzyme 12, 561-573.
6. Bonoczk, P., Gulyas, B., Adam-Vizi, V., Nemes, A., Karpati, E., Kiss, B., Kapas, M., Szantay, C., Koncz, I., Zelles, T., Vas, A. (2000) Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res. Bull. 53, 245-254.
7. Crowley, L. V. (1967) The Reitman-Frankel colorimetric transaminase procedure in suspected myocardial infarction. Clin. Chem. 13, 482-487.
8. Farghali, H., Kamenikova, L., Hynie, S., Kmonickova, E. (2000) Silymarin effects on intracellular calcuim and cytoxicity: a study in perfused rat hepatocytes after oxidative stress injury. Pharmacol. Res. 41, 231-237.
9. Flora, K., Hahn, M., Rosen, H., Benner, K. (1998) Milk thistle (Silybum marianum) for the therapy of liver disease. Am. J. Gastroenterol. 93, 139-143.
10. Fried, M. W. (2002) Side effects of therapy of hepatitis C and their management. Hepatology 36, S237-S244.
11. Hadjiev, D. (2003) Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyógy. Szemle 56, 166-172.
12. Hsu, C. T., Schichijo, K., Ito, M., Sekine, I. (1993) The effect of chemical sympathectomy on acute liver injury induced by carbon tetrachloride in spontaneously hypertensive rats. J. Auton. Nerv. Syst. 43, 91-96.
13. 4 induced hepatotoxicity. Acta Pharm. Hung. 66, 213-224.
14. Landon, E. J., Naukam, R. J., Rama-Sastry, B. V. (1986) Effects of calcium channel blocking agents on calcium and centrilobular necrosis in the liver of rats treated with hepatotoxic agents. Biochem. Pharmacol. 35, 697-705.
15. Lillestll, I. K., Helle, K. B., Aardal, S. (1998) Relaxing effects of cyclic GMP and cyclic AMP-enhancing agents on the long-lasting contraction to endothelin-1 in the porcine coronary artery. Scand. J. Clin. Lab. Invest. 58, 625-634.
16. Maher, J. J. (2001) Interactions between hepatic stellate cells and the immune system. Semin. Liver Dis. 21, 417-426.
17. Manns, M. P., McHutchison, J. G., Gordon, S. C. et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965.
18. Marcellin, P., Asselah, T., Boyer, N. (2002) Fibrosis and disease progression in hepatitis C. Hepatology 36, S47-56.
19. McCaughan, G. W., George, J. (2004) Fibrosis progression in chronic hepatitis C virus infection. Gut 53, 318-321.
20. Muriel, P., Mourelle, M. (1990) Prevention by silymarin of membrane alterations in acute CCl4 liver damage. J. Appl. Toxicol. 10, 275-279.
21. Nekrassov, V., Sitges, M. (2000) Vinpocetine protects from aminoglycoside antibiotic-induced hearing loss in guinea pig in vivo. Brain. Res. 868, 222-229.
22. Paget, G. E., Barnes, J. M. (1964) In: Laurence, D. R., Bacharach, A. L. (eds) Evaluation of Drug Activities Pharmacometics. Academic Press, London & NewYork, pp. 1-135.
23. Pianko, S., McHutchison, J. G. (2000) Treatment of hepatitis C with interferon and ribavirin. J. Gastroenterol. Hepatol. 15, 581-586.
24. Romero, G., Lasheras, B., Sainz-Suberviola, L., Cenarruzabeitia, E. (1994) Protective effects of calcium channel blockers in carbon tetrachloride-induced liver toxicity. Life Sci. 55, 981-990.
25. Sippel, H., Stauffert, I., Estler, C. J. (1993) Protective effect of various calcium antagonists against an experimentally induced calcium overload in isolated hepatocytes. Biochem. Pharmacol. 46, 1937-1944.
26. Sitges, M., Galvan, E., Nekrassov, V. (2005) Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosomes. Neurochem. Int. 46, 533-540.
27. Tanaka, N., Tanaka, K., Nagashima, Y., Kondo, M., Sekihara, H. (1999) Nitric oxide increases hepatic arterial blood flow in rats with carbon tetrachloride-induced acute hepatic injury. Gastroenterology 117, 173-180.
28. Szakács, T., Veres, Zs., Vereczkey, L. (2001) In vitro-in vivo correlation of the pharmakokinetics of vinpocetine. Pol. J. Pharmacol. 53, 623-628.
29. Vas, A., Gulyas, B., Szabo, Z., Bonoczk, P., Csiba, L., Kiss, B., Karpati, E., Panczel, G., Nagy, Z. (2002) Clinical and non-clinical investigations using positron emission tomography, near infrared spectroscopy and transcranial Doppler methods on the neuroprotective drug vinpocetine: a summary of evidences. J. Neurol. Sci. 203-204, 259-262.
30. Wellington, K., Jarvis, B. (2001) Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15, 465-489.
31. + channels: physiological role and pharmacology. Curr. Med. Chem. 10, 649-661.